The Department of Defense (DoD) Prostate Cancer Research Program (PCRP) is offering the Transformative Impact Award to support research revolutionizing prostate cancer clinical management. This grant aims for near-term clinical relevance, significantly contributing to the elimination of deaths and enhancing men’s well-being. Projects should involve translational research, clinical research, and/or clinical trials, addressing PCRP challenges and focus areas. Applicants must provide substantive preliminary data, a detailed implementation plan, and ensure accessibility to human subjects/samples. An exceptionally skilled research team with a robust communication plan is expected, with multi-institutional collaboration encouraged through the Partnering PI Option. An oral presentation is a required component of the application review process.
Opportunity ID: 234434
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-PCRP-TIA |
| Funding Opportunity Title: | DoD Prostate Cancer Transformative Impact Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 13, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Oct 09, 2013 |
| Current Closing Date for Applications: | Oct 09, 2013 |
| Archive Date: | Nov 08, 2013 |
| Estimated Total Program Funding: | $8,000,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The PCRP Transformative Impact Award mechanism was first offered in FY12. Since then, 10 Transformative Impact Award applications have been received, and 3 have been recommended for funding. The Transformative Impact Award supports prostate cancer research with near-term clinical relevance that will transform and revolutionize the clinical management of prostate cancer and make a major contribution to the elimination of death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease. For the purpose of this award, clinical management of prostate cancer includes the wide spectrum of screening, detection, diagnosis, prognosis, and/or treatment. Although research that is deemed transformative must contend with potential risks, the proposed project(s) must be supported by thorough review of the literature, a sound rationale, and a well-designed research strategy. Applications must include substantive preliminary data to support the rationale and feasibility of the study. The critical components of this award mechanism are: Research Scope: Since the intent of this award is to achieve near-term clinical impact for patients, the scope of the research effort is expected to include translational research, clinical research, and/or clinical trials. All projects submitted to the Transformative Impact Award mechanism must address one of the PCRP overarching challenges and are expected to address at least one of the PCRP focus areas. Transformative Impact: Projects funded by this award will have a near-term, revolutionary impact on the clinical management of prostate cancer. It is the responsibility of the Principal Investigator (PI) to clearly and sufficiently describe how the proposed project(s) will transform prostate cancer clinical management in the near term. Implementation Plan: The project(s) must be supported by a detailed plan that identifies critical milestones, outlines the knowledge, expertise, and technical innovations that the investigative team will utilize to achieve the milestones and explains how the outcomes of the project(s) will be translated to patients. The application must include information demonstrating accessibility and availability of human subjects and/or human anatomical samples, substances, and/or data necessary for the study so that the project(s) can commence immediately after an award is made. PIs whose study design(s) require human anatomical substances are encouraged to collaborate with personnel affiliated with established prostate cancer biorepositories (e.g., Prostate Cancer Biorepository Network [PCBN] [http://www.prostatebiorepository.org] and/or the North Carolina Louisiana Prostate Cancer Project [PCaP] [http://www.ncla-pcap.org]). A robust statistical plan and statistical expertise should be included where appropriate in proposed investigation(s). Research Team: It is expected that the proposed research team will include an exceptionally skilled group of individuals (e.g., scientists, clinicians, consumer advocates, etc.) well positioned to achieve the goals, with leadership from multiple collaborators. The PI(s) should possess a track record of success in leading large, focused projects with clinical impact. The PI(s) also should demonstrate a strong commitment to the project and to the research team, and develop a communications plan that fosters consistent and intensive interactions by all team members to accelerate translation of the projects outcomes to patients and/or for clinical use. The inclusion of scientific advisors, external to the conduct of the research, is encouraged. The PCRP Science Officer assigned to any resulting award must be invited to participate in periodic research team meetings. The plan for such meetings should be noted in the application. Partnering PI Option: The Transformative Impact Award mechanism encourages multi-institutional applications. The Partnering PI Option under this award mechanism is structured to accommodate up to three PIs, each of whom will receive a separate award. One partner is identified as the Initiating PI and additional PIs are identified as Partnering PIs. The Initiating and Partnering PIs have different application submission requirements; however, each PI should contribute to the preparation of each of the application components. The PIs may have expertise in similar or disparate scientific disciplines. It is the responsibility of the collaborating investigators to describe how their efforts will combine and synergize to maximize the projects outcomes. Oral Presentation: An oral presentation to the PCRP Integration Panel (IP) is a requirement for application review as described below: Programmatic Review, Stage 2: A PI or Initiating PI whose application is selected for final consideration in Stage 2 of the Programmatic Review will be required to give an oral presentation that will be held in the National Capital Area in March 2014. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 234434 Full Announcement-1 -> pcrp fy13 tia pa_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00177613 | May 13, 2013 | Oct 09, 2013 | View |
Package 1
Mandatory forms
234434 RR_SF424_1_2-1.2.pdf
234434 PerformanceSite_1_4-1.4.pdf
234434 RR_Budget-1.1.pdf
Optional forms
234434 RR_SubawardBudget30-1.2.pdf
234434 RR_KeyPersonExpanded_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
